Drug Therapy
Showing 9976 - 10000 of >10,000
Iron Deficiency Anemia Trial (Triferic AVNU, Placebo)
Not yet recruiting
- Iron Deficiency Anemia
- Triferic AVNU
- Placebo
- (no location specified)
Oct 26, 2021
Androgen Deprivation-related Sarcopenia
Recruiting
- Metastatic Prostate Cancer
- Androgen Deprivation Therapy
- GnRH agonist
-
Seattle, WashingtonVeterans Affairs Puget Sound Health Care System
Mar 16, 2022
Sarcoma Trial in France (Nivolumab and IPILIMUMAB, Pazopanib Oral Tablet [Votrient])
Recruiting
- Sarcoma
- Nivolumab and IPILIMUMAB
- Pazopanib Oral Tablet [Votrient]
-
Lyon, Rhône, France
- +10 more
Jun 22, 2022
Unresectable Metastatic Colorectal Cancer Trial (Bifico combined with chemo plus targeted therapy, chemo plus targeted therapy)
Not yet recruiting
- Unresectable Metastatic Colorectal Cancer
- Bifico combined with chemotherapy plus targeted therapy
- chemotherapy plus targeted therapy
- (no location specified)
Jul 13, 2021
Covid19, Lymphopenia Trial in Shenyang (nicotinamide)
Completed
- Covid19
- Lymphopenia
-
Shenyang, Liaoning, ChinaGeneral Hospital of Northern Theater Command
Oct 29, 2021
Gastrointestinal Neuroendocrine Carcinoma Trial in Beijing (Durvalumab and Chemotherapy(oxaliplatin and capecitabine))
Recruiting
- Gastrointestinal Neuroendocrine Carcinoma
- Durvalumab and Chemotherapy(oxaliplatin and capecitabine)
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Oct 1, 2023
Atrial Fibrillation Trial in Indianapolis (Ondansetron 8mg, Placebo)
Not yet recruiting
- Atrial Fibrillation
- Ondansetron 8mg
- Placebo
-
Indianapolis, Indiana
- +2 more
Apr 25, 2023
Alzheimer Trial in Atlanta (Montelukast, Placebo oral tablet)
Active, not recruiting
- Alzheimer Disease
- Montelukast
- Placebo oral tablet
-
Atlanta, Georgia
- +3 more
Nov 16, 2021
Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,
Not yet recruiting
- Breast Cancer Invasive
- +3 more
- Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
- Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nov 17, 2023
Chronic Hepatitis B Trial in Guangzhou (NrtIs, HH-003, HH-003+NrtIs)
Active, not recruiting
- Chronic Hepatitis B
- NrtIs
- +2 more
-
Guangzhou, Guangdong, ChinaNanfang Hospital, Southern Medical University
Apr 20, 2023
Subcutaneous Fat Disorder Trial (10XB-101 Solution for Injection, 6.0%, Placebo Solution for Injection (no active ingredient))
Not yet recruiting
- Subcutaneous Fat Disorder
- 10XB-101 Solution for Injection, 6.0%
- Placebo Solution for Injection (no active ingredient)
- (no location specified)
Feb 27, 2023
Complex Regional Pain Syndrome Trial in Cleveland (Nitrous Oxide, Oxygen)
Enrolling by invitation
- Complex Regional Pain Syndrome
- Nitrous Oxide
- Oxygen
-
Cleveland, OhioCleveland Clinic Pain Management
Jan 10, 2022
Substance Use Disorders, PTSD Trial in Aurora, Centennial, Denver (RRFT (Risk Reduction through Family Therapy), ENCOMPASS
Recruiting
- Substance Use Disorders
- PTSD
- RRFT (Risk Reduction through Family Therapy)
- ENCOMPASS (Integrated Treatment for Adolescents and Young Adults)
-
Aurora, Colorado
- +2 more
Aug 2, 2022
Radium-223 is and How Well it Works in Chinese Advanced Prostate
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer
- Bone Metastases
- Radium-223 dichloride (Xofigo, BAY88-8223)
-
Multiple Locations, ChinaMany locations
Aug 10, 2022
Obstructive Sleep Apnea of Adult Trial in New York (Atorvastatin 10mg, Placebo, Continuous Positive Airway Pressure Therapy)
Recruiting
- Obstructive Sleep Apnea of Adult
- Atorvastatin 10mg
- +2 more
-
New York, New YorkColumbia University Irving Medical Center
Jan 25, 2023
Ischemic Stroke Trial in Hangzhou (Nerver growth factor (NGF) injection, Placebo injection, EA intervention)
Recruiting
- Ischemic Stroke
- Nerver growth factor (NGF) injection
- +3 more
-
Hangzhou, Zhejiang, ChinaThe Third Affiliated Hospital of Zhejiang Chinese Medical Univer
Jul 26, 2022
Leukemia Trial in Houston (MEK 162)
Terminated
- Leukemia
- MEK 162
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Mar 25, 2021